Latest news and press releases about Septerna Inc (SEPN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Price
| Price | $38.44 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.63 |
| EV / EBITDA | -41.49 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -8.89% |
| Return on Assets | -4.28% |
| Gross Margin | 99.57% |
| Operating Margin | -44.04% |
| Net Margin | -24.51% |
Related companies: ABUS · BCAX · EYPT · FTRE · KURA · MRVI · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks